Neo-Adjuvant:

ECOG E2205: Radiation Therapy with Oxaliplatin, continuous infusion 5FU and Cetuximab the surgery followed by Docetaxel and Cetuximab

ECOG 80403: Epirubicin, Cisplatin, Continuous Infusion 5FU and Cetuximab (ECF-C) versus Irinotecan, Cisplatin and Cetuximab (IC-C) versus Oxalipatin, Leucovorin, 5FU (FOLFOX) and Cetuximab

RTOG 0436: Cetuximab, Paclitaxel, Cisplatin and Radiation Therapy

ECOG 80403: Epirubicin, Cisplatin, Continuous Infusion 5FU and Cetuximab (ECF-C) versus Irinotecan, Cisplatin and Cetuximab (IC-C) versus Oxalipatin, Leucovorin, 5FU (FOLFOX) and Cetuximab

Schering Plough P04273: Temozolomide for CA selected for methylation of O6 methyl-guanine DNA Methyl-transferase promoter--May have received one prior treatment

Gastric or GE Junction

ECOG 80403: Epirubicin, Cisplatin, Continuous Infusion 5FU and Cetuximab (ECF-C) versus Irinotecan, Cisplatin and Cetuximab (IC-C) versus Oxalipatin, Leucovorin, 5FU (FOLFOX) and Cetuximab (Includes the GE Junction only)

Schering Plough P04273: Temozolomide for CA selected for methylation of O6 methyl-guanine DNA Methyl-transferase promoter--May have received one prior treatment

Pancreas

None

CST 15721BUS227: Registry Study

CTSU S0502: Imatinib with or without Bevacizumab

Colon

ECOG E5202: (T3-4,N0, M0) Parafin tissue block sent for microsatellite instability & loss of heterozygosity at 18q--If low risk, then Observation and If high risk, then FOLFOX (Oxaliplatin / 5FU / Leucovorin) with or without Bevacizumab

Stage III: CTSU N0147: . FOLFOX (Oxaliplatin / 5FU / Leucovorin) with or without C225

None

CTSU C80405: FOLFOX (Oxaliplatin / 5FU / Leucovorin) or FOLFIRI (Irinotecan / 5FU/ Leucovorin) with or without Bevacizumab

ECOG E4203: Treatment based on TS Expression:

High TS Expression: IROX + Bevacizumab versus FOLFOX + Bevacizumab

Low TS Expression: FOLFOX + Bevacizumab

Second Line Treatment:

CTSU S0600: Irinotecan based chemo + Cetuximab with or without Bevacizumab--2nd line treatment for patients whos hve progressed on Bevacizumab with either FOLFOX, OPTIMOX or XELOX (Suspended 6/08)

Pre operative treatments :

NSABP R-04: Radiation Therapy and Capecitabine, then Surgery versus Radiation Therapy and continous 5FU, then Surgery

Stage II or III - ECOG E5204: FOLFOX (Oxaliplatin / 5FU / Leucovorin) with or without Bevacizumab after surgery

ECOG E3204: RT + concurrent Capecitabine, Oxalipatin, and Bevacizumab then surgery and post operative FOLFOX and bevacizumab

None